Pharmaceutical Shares of Everest Medicines shot up 10% to HK$17.38 today, after it announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has recommended Priority Review for the New Drug Application (NDA) of Nefecon, a new oral formulation of budesonide, for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression. 30 December 2022